Company Description
Lexaria Bioscience Corp. operates as a biotechnology company.
It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
The company’s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Richard Christopher |
Contact Details
Address: 740 McCurdy Road, Suite 100 Kelowna, BC V1X 2P7 Canada | |
| Phone | 250 765 6424 |
| Website | lexariabioscience.com |
Stock Details
| Ticker Symbol | LEXX |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001348362 |
| CUSIP Number | 52886N406 |
| ISIN Number | US52886N4060 |
| Employer ID | 20-2000871 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard C. Christopher | Chief Executive Officer |
| John M. Docherty M.Sc. | President and Director |
| Michael Shankman CPA | Chief Financial Officer |
| Kristin Hamilton | Director of Operations |
| Vanessa Carle | Head of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 16, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 16, 2024 | 424B5 | Filing |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 22, 2024 | 8-K | Current Report |